(6R,8R,9S,13S,14S)-6-(6-methoxyhexyl)-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol | 1227511-09-2

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: (6R,8R,9S,13S,14S)-6-(6-methoxyhexyl)-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol
• 英文别名: NDC-1308；GM32Bya54Z；(6R,8R,9S,13S,14S,17S)-6-(6-methoxyhexyl)-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol
• CAS: 1227511-09-2
• 化学式: C₂₅H₃₈O₃
• 分子量: 386.575
• InChiKey: WIJIRYKVMWGBHO-NXYDILSSSA-N

物化性质

• 沸点：
  524.8±50.0 °C(Predicted)
• 密度：
  1.076±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  6
• 重原子数：
  28
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.76
• 拓扑面积：
  49.7
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  2-((6S,8R,9S,13S,14S,17S)-3,17-bis(methoxymethoxy)-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-6-yl)acetaldehyde 在 盐酸 、 palladium 10% on activated carbon 、 水 、 氢气 、 sodium hydride 、 戴斯-马丁氧化剂 、 lithium hexamethyldisilazane 作用下， 以 四氢呋喃 、 二氯甲烷 、 乙酸乙酯 为溶剂， 反应 27.67h， 生成 (6R,8R,9S,13S,14S)-6-(6-methoxyhexyl)-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol
  参考文献：
  名称：

  METHODS FOR MODULATION OF LIPOPROTEIN LIPASE AND APOLIPOPROTEIN C2 EXPRESSION AND/OR ACTIVITY IN THE TREATMENT OF PERIPHERAL AND CENTRAL NERVOUS SYSTEM TISSUE DISEASE STATES

  摘要：

  本文提出了使用C-6取代的雌二醇衍生物调节脂蛋白酯酶（LPL）和载脂蛋白C2（ApoC2）表达和/或活性的方法，用于治疗外周和中枢神经系统组织疾病状态。

  公开号：

  US20210024568A1

文献信息

• 6-SUBSTITUTED ESTRADIOL DERIVATIVES AND METHODS OF USE
  申请人：Yarger James G.

  公开号：US20100130463A1

  公开（公告）日：2010-05-27

  Disclosed are compounds of the formula: wherein R 1 , R 2 , R 3 and R 4 are independently hydrogen, C 1 -C 6 alkyl, halo, a sulfate, a glucuronide, —OH, a bulky group, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, —N(CH 2 ) n ; a phosphate group, and a phosphinate group; R 9 is hydrogen, halogen or alkyl; R 11 is selected from the group consisting of H, C 1 -C 6 alkyl, halogen, a sulfate, a glucoronide, —SO 2 NH 2 , —COOH, —CN, —CH 2 CN—, —NHCN—, —CHO, ═CHOCH 3 , —COO salt, —OSO 2 alkyl, —NH 2 , and —NHCO(CH 2 ) n ; R 12 is selected from the group consisting of H, a C 1 -C 6 alkyl, a sulfate, a glucoronide, a bulky group, aryl, cycloalkyl, heteroaryl and heterocycloalkyl; X is selected from the group consisting of C 1 -C 12 alkyl, C 2 -C 12 alkenyl, C 2 -C 12 alkynyl, halogen, a glucoronide, —NH 2 , —SO 2 NH 2 , —COOH, —CN, —CH 2 CN, —NHCN, —CHO, —COOsalt, —OSO 2 alkyl, —SH, —SCH 3 , —CH[(CH 2 ) n CH 2 ]COOCH 2 , —(CH 2 ) m COOCH 3 , —(CH 2 ) m —O—CH 3 , —(CH 2 ) m —O—(CH 2 ) n CH 3 , (CH 2 ) m —S—CH 3 , —(CH 2 ) m —S—(CH 2 ) n CH 3 , —(CH 2 ) m —NH—(CH 2 ) n CH 3 , —C 2 -C 8 alkenyl-O—(CH 2 ) n CH 3 , —C 2 -C 8 alkenyl-S—(CH 2 ) n CH 3 , —C 2 -C 8 alkenyl-N—(CH 2 ) n CH 3 , —C 2 -C 8 alkynyl-O—(CH 2 ) n CH 3 , —C 2 -C 8 alkynyl-S—(CH 2 ) n CH 3 , —C 2 -C 8 alkynyl-N—(CH 2 ) n CH 3 , —(CH 2 ) m —OH, —(CH 2 ) m —O—NH 2 , —(CH 2 ) m —S—NH 2 , —NH(CH 2 ) m CH 3 , —NH(CH 2 ) m OCH 3 , —NH(CH 2 ) m CHOH—COOH, —N(CH 3 ) 2 , —(CH 2 ) m (NH)CH 2 OH, —NHCOOH, —(CH 2 ) m NHCOOH, —NO 2 , —SCN, —SO 2 alkyl, —B(OH) 2 , —(CH 2 ) m N(CH 3 )—SO 2 —NH 3 , —(CH 2 ) m —NH—SO 2 —NH 2 , —NHC(═S)CH 3 , and —NHNH 2 ; and Y is selected from hydrogen, ═O, —OCO(R 6 ) and —OH; wherein m is an integer between 0-20, n is an integer between 0-8, the symbol represents either a single or a double bond capable of forming a keto group at position 3 or 17; and the symbol represents any type of bond regardless of the stereochemistry; and the respective enantiomers, other stereochemical isomers, hydrates, solvates, tautomers and pharmaceutically acceptable salts of said compounds. The compounds are useful in the treatment of various types of cancer.

  公开了以下式子的化合物：其中R1、R2、R3和R4独立地为氢、C1-C6烷基、卤素、硫酸盐、葡萄糖醛酸盐、—OH、笨重基团、芳基、环烷基、杂芳基、杂环烷基、—N(CH2)n、磷酸盐和亚磷酸盐；R9为氢、卤素或烷基；R11选自H、C1-C6烷基、卤素、硫酸盐、葡萄糖醛酸盐、—SO2NH2、—COOH、—CN、— CN—、—NHCN—、—CHO、═CHO 、—COO盐、—OSO2烷基、—NH2和—NHCO( )n；R12选自H、C1-C6烷基、硫酸盐、葡萄糖醛酸盐、笨重基团、芳基、环烷基、杂芳基和杂环烷基；X选自C1-C12烷基、C2-C12烯基、C2-C12炔基、卤素、葡萄糖醛酸盐、—NH2、—SO2NH2、—COOH、—CN、— CN、—NHCN、—CHO、—COO盐、—OSO2烷基、—SH、—S 、—CH[( )n ]COO 、—( )mCOO 、—( )m—O—CH3、—( )m—O—( )n 、( )m—S— 、—( )m—S—( )n 、—( )m—NH—( )n 、—C2-C8烯基-O—( )n 、—C2-C8烯基-S—( )n 、—C2-C8烯基-N—( )n 、—C2-C8炔基-O—( )n 、—C2-C8炔基-S—( )n 、—C2-C8炔基-N—( )n 、—( )m—OH、—( )m—O—NH2、—( )m—S—NH2、—NH( )m 、—NH( )mO 、—NH( )mCHOH—COOH、—N( )2、—( )m(NH) OH、—NHCOOH、—( )mNHCOOH、—NO2、—SCN、—SO2烷基、—B(OH)2、—( )mN( )—SO2—NH3、—( )m—NH—SO2—NH2、—NHC(═S) 和—NHNH2；Y选自氢、═O、—OCO(R6)和—OH；其中m为0-20之间的整数，n为0-8之间的整数，符号表示能够在位置3或17形成酮基的单一或双键；符号表示任何类型的键，不考虑立体化学；以及所述化合物的相应对映异构体、其他立体化学异构体、水合物、溶剂化物、互变异构体和药学上可接受的盐。该化合物在治疗各种类型的癌症中有用。
• 6-substituted estradiol derivatives and methods of use
  申请人：Yarger James G.

  公开号：US10174070B2

  公开（公告）日：2019-01-08

  Disclosed are compounds of the formula: wherein R1, R2, R3 and R4 are independently hydrogen, C1-C6 alkyl, halo, a sulfate, a glucuronide, —OH, a bulky group, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, —N(CH2)n; a phosphate group, and a phosphinate group; R9 is hydrogen, halogen or alkyl; R11 is selected from the group consisting of H, C1-C6 alkyl, halogen, a sulfate, a glucoronide, —SO2NH2, —COOH, —CN, —CH2CN—, —NHCN—, —CHO, ═CHOCH3, —COO salt, —OSO2alkyl, —NH2, and —NHCO(CH2)n; R12 is selected from the group consisting of H, a C1-C6 alkyl, a sulfate, a glucoronide, a bulky group, aryl, cycloalkyl, heteroaryl and heterocycloalkyl; X is selected from the group consisting of C1-C12 alkyl, C2-C12 alkenyl, C2-C12 alkynyl, halogen, a glucoronide, —NH2, —SO2NH2, —COOH, —CN, —CH2CN, —NHCN, —CHO, —COOsalt, —OSO2alkyl, —SH, —SCH3, —CH[(CH2)nCH3]COOCH3, —(CH2)mCOOCH3, —(CH2)m—O—CH3, —(CH2)m—O—(CH2)nCH3, (CH2)m—S—CH3, —(CH2)m—S—(CH2)nCH3, —(CH2)m—NH—(CH2)nCH3, —C2-C8 alkenyl-O—(CH2)nCH3, —C2-C8 alkenyl-S—(CH2)nCH3, —C2-C8 alkenyl-N—(CH2)nCH3, —C2-C8 alkynyl-O—(CH2)nCH3, —C2-C8 alkynyl-S—(CH2)nCH3, —C2-C8 alkynyl-N—(CH2)nCH3, —(CH2)m—OH, —(CH2)m—O—NH2, —(CH2)m—S—NH2, —NH(CH2)mCH3, —NH(CH2)mOCH3, —NH(CH2)mCHOH—COOH, —N(CH3)2, —(CH2)m(NH)CH2OH, —NHCOOH, —(CH2)mNHCOOH, —NO2, —SCN, —SO2alkyl, —B(OH)2, —(CH2)mN(CH3)—SO2—NH3, —(CH2)m—NH—SO2—NH2, —NHC(═S) CH3, and —NHNH2; and Y is selected from hydrogen, ═O, —OCO(R6) and —OH; wherein m is an integer between 0-20, n is an integer between 0-8, the symbol represents either a single or a double bond capable of forming a keto group at position 3 or 17; and the symbol represents any type of bond regardless of the stereochemistry; and the respective enantiomers, other stereochemical isomers, hydrates, solvates, tautomers and pharmaceutically acceptable salts of said compounds. The compounds are useful in the treatment of various types of cancer.

  公开了式中的化合物： 其中 R1、R2、R3 和 R4 独立地为氢、C1-C6 烷基、卤素、硫酸根、葡糖醛酸根、-OH、稠合基、芳基、环烷基、杂芳基、杂环烷基、-N(CH2)n；磷酸基和膦酸基；R9 为氢、卤素或烷基；R11 选自由 H、C1-C6 烷基、卤素、硫酸盐、葡萄糖酸盐、-SO2NH2、-COOH、-CN、- CN-、-NHCN-、-CHO、═CHO 、-COO 盐、-OSO2 烷基、-NH2 和 -NHCO( )n 组成的组；R12 选自由 H、C1-C6 烷基、硫酸酯、葡糖酸酯、稠密基团、芳基、环烷基、杂芳基和杂环烷基组成的组；X 选自由 C1-C12 烷基、C2-C12 烯基、C2-C12 炔基、卤素、葡糖醛酸、-NH2、-SO2NH2、-COOH、-CN、- CN、-NHCN、-CHO、-COOSalt、-OSO2 烷基、-SH、-S 、-CH[( )n ]COO 、-( )mCOO 、-( )m-O-CH3、-( )m-O-( )n 、( )m-S- 、-( )m-S-( )n 、-( )m-NH-( )n 、-C2-C8 烯基-O-( )n 、-C2-C8 烯基-S-( )n 、-C2-C8烯基-N-( )n ，-C2-C8炔基-O-( )n ，-C2-C8炔基-S-( )n ，-C2-C8炔基-N-( )n ，-( )m-OH，-( )m-O-NH2，-( )m-S-NH2，-NH( )m ，-NH( )mO 、-NH( )mCHOH-COOH、-N( )2、-( )m(NH) OH、-NHCOOH、-( )mNHCOOH、-NO2、-SCN、-SO2 烷基、-B(OH)2、-( )mN( )-SO2-NH3、-( )m-NH-SO2-NH2、-NHC(═S) 和 -NHNH2；Y选自氢、═O、-OCO(R6)和-OH；其中m为0-20之间的整数，n为0-8之间的整数，符号代表能在第3位或第17位形成酮基的单键或双键；符号代表任何类型的键（无论其立体化学性质如何）；以及所述化合物各自的对映体、其他立体化学异构体、水合物、溶解物、同系物和药学上可接受的盐。这些化合物可用于治疗各种类型的癌症。
• [EN] PHOSPHAMIDE DERIVATIVE, METHOD FOR MANUFACTURING THE SAME, AND USES THEREOF<br/>[FR] DÉRIVÉ DE PHOSPHAMIDE, SON PROCÉDÉ DE FABRICATION ET SES UTILISATIONS<br/>[ZH] 一种磷酰胺衍生物及制备方法和用途
  申请人：SICHUAN HAISCO PHARMACEUTICAL CO LTD

  公开号：WO2017133517A1

  公开（公告）日：2017-08-10

  公开了一种磷酰胺衍生物及制备方法和用途。特别公开了一种通式(I)所示化合物及其药学上可接受的盐或立体异构体 (I)，其中，G、L、Q、s如说明书中所定义。
• 6-SUBSTITUTED ESTRADIOL DERIVATIVES FOR USE IN REMYELINATION OF NERVE AXONS
  申请人：Endece, LLC

  公开号：EP2688570B1

  公开（公告）日：2015-11-18
• 6-Substituted Estradiol Derivatives for the Treatment of Alzheimer's Disease
  申请人：Endece LLC

  公开号：US20150265630A1

  公开（公告）日：2015-09-24

  Disclosed is a method of treating Alzheimer's Disease with 6-substituted estradiol compounds of the formula The methods can be used to treat a variety of diseases related to the up-regulation of lipoprotein lipase or apolipoprotein C2.